Press & Statements

Senate Special Committee on Aging Examines Drug Pricing

Mar 17, 2016

"Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It’s unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice.” Read More

FDA to Prioritize Generic Drug Applications

Mar 15, 2016

"Recently, the FDA took an important first step in acknowledging the need to introduce more competition by prioritizing generic applications where there is no competition. This effort will give patients better access to affordable treatments," said John Rother, executive director of the Campaign for Sustainable Rx Pricing. Read More

AARP Joins Campaign for Sustainable Rx Pricing

Mar 3, 2016

Today the National Coalition of Health Care announced that AARP has officially joined the coalition’s Campaign for Sustainable Rx Pricing. AARP is a nonprofit, nonpartisan organization, with a membership of nearly 38 million Americans and shares the Campaign’s goal of finding market-based solutions to reverse the trend of high and rising prescription drug prices. Read More

AARP Report Finds Dramatic Prescription Price Hikes

Feb 29, 2016

“Today’s AARP report provides new evidence that drug companies are raising prescription drug prices on patients indiscriminately. Specialty and branded drugs alike are going up six times faster than inflation. The exorbitant increases make health care more expensive for families, taxpayers, and job creators and put a major strain on federal and state governments. It's going to take market-based policy solutions to deal with this unsustainable trend.” Read More

Statement on President Obama’s FY 2017 Proposed Budget

Feb 9, 2016

"Today the president took an important step in his FY 2017 Budget to support transparency in the market and provide new information to consumers. CSRxP welcomes this step and encourages Congress and the Administration to take action to make prescription drugs affordable for all Americans.” Read More

John Rother Statement on House Oversight Committee Hearing

Feb 4, 2016

“Prescription drug cost hikes are not limited to companies run by people like Martin Shkreli; they are commonplace in the pharmaceutical industry. This issue transcends political party lines because consumers, patients, and public programs across the country simply cannot afford higher prices for medication." Read More

Prescription Drug Costs are a Bigger Problem than just Martin Shkreli

Feb 3, 2016

Prescription drug prices are rising at an alarming pace and the problem is far more widespread than a few bad actors. Read More

Shkreli and Big Pharma’s Price Gouging are One and the Same

Feb 3, 2016

In just the past year, prices have been jacked up on hundreds of medications. The dirty secret is that Big Pharma's price increases far exceed Daraprim’s. They contribute to BILLIONS in Medicare spending and are used by MILLIONS of Medicare beneficiaries. Below we will take a look at just 30 of those medications. Read More

American Society of Health-System Pharmacists Joins the Campaign for Sustainable Rx Pricing

Feb 3, 2016

"ASHP joins the Campaign at an important time and adds a crucial voice to our effort. Pharmacists are on the frontlines of the fight to make prescription drugs affordable,” noted John Rother, executive director of the Campaign for Sustainable Rx Pricing. "We are thrilled to have ASHP join this effort as we seek to find market-based solutions that can reduce drug prices for consumers, providers, and the U.S health care system." Read More

Anthem and Eli Lilly Announce Collaborative Effort to Combat High Cost Drugs

Jan 29, 2016

"I am encouraged to see Eli Lilly and Anthem begin a dialogue around increasing prescription drug prices. Their collaboration illustrates the widespread effort needed to find a sustainable, market-based solution, but it is just one step on a long road." Read More

Pfizer Hikes Prices on More Than 100 Existing Prescription Drugs

Jan 11, 2016

“Again and again, drug companies like Pfizer raise prices of prescriptions that have already been on the market for years which hurts patients trying to make ends meet and public programs dealing with difficult budgets. These increases, compounded year after year, are simply unsustainable. It’s not about innovation or research; it’s price gouging.” Read More

Campaign for Sustainable Rx Pricing Announces Communications Director

Jan 8, 2016

The Campaign for Sustainable Rx Pricing (CSRxP) is pleased to announce that Allison Schneider has joined as communications director. Allison will lead the Campaign’s communications efforts both inside the beltway in Washington, D.C. and with state and local media throughout the country. Read More